Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer's Dementia

Suven Life Sciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for central nervous system (CNS) disorders, today announced the 76% enrolment milestone in its 375-patient, multi-center, randomized, double-blind, placebo-controlled Global Phase-3 study (NCT05397639, EudraCT Number 2021-003405-22) for the treatment of agitation in patients with dementia of the Alzheimer's type (AAD) of its proprietary Phase 3 clinical candidate Masupirdine. The study is conducted across North America (USA) and Europe.

"This milestone reflects continued momentum in the program, completion of patient enrolment by End of calendar 2026 is certain if not earlier and last patient last visit will be in qtr. 1, 2027 enabling progression towards database lock and reporting of results potentially in Q2/ Q3-2027 calendar year. Patient enrolment activity has been accelerated through multiple additional resources, experienced investigators, medical experts, AI enabled patient identification and referral to the sites. Our goal is to advance the study towards completion with definitive timelines" said Mr. Venkat Jasti, Chairman and Managing Director of the Company.

"Agitation is a common neuropsychiatric symptom of dementia due to Alzheimer's disease, and it is associated with increased caregiver burden and need for rapid institutionalization. Current treatment options are constrained by limited efficacy and concerns about tolerability and safety. Masupirdine a pure, potent, and selective 5-HT6 receptor antagonist with all the potential to offer a differentiated, non-dopaminergic, non-sedative approach transforming Alzheimer's agitation (AAD) management, delivering dual impact on behavioral stabilization and cognition" said Dr. Ramakrishna Nirogi, President and CSO of Suven Life Sciences.

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies and are representative of an Alzheimer's disease population with agitation. Suven and the CRO teams working towards the enrollment of Last Patient In (LPI) by September 2026 and Last Patient Last Visit (LPLV) by January 2027. Data readout is expected by April 2027.

Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 215.25 as compared to the previous close of Rs. 218.35. The total number of shares traded during the day was 34488 in over 640 trades.

The stock hit an intraday high of Rs. 223.20 and intraday low of 207.50. The net turnover during the day was Rs. 7282577.00.

Source : Equity Bulls

Keywords

SuvenLifeSciences INE495B01038 Pharmaceuticals SUVN502 GlobalPhase3Study